СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПОРАЖЕНИИ ПОЧЕК ПРИ ОЖИРЕНИИ


Цитировать

Полный текст

Аннотация

Обсуждаются механизмы развития, клинические варианты и прогностическое значение поражения почек при ожирении.

Об авторах

Е А Сагинова

Кафедра терапии и профболезней ММА им. И.М. Сеченова, Москва

Кафедра терапии и профболезней ММА им. И.М. Сеченова, Москва

М Г Галлямов

Кафедра внутренних болезней факультета фундаментальной медицины МГУ им. М.В. Ломоносова, Москва

Кафедра внутренних болезней факультета фундаментальной медицины МГУ им. М.В. Ломоносова, Москва

М В Северова

Кафедра внутренних болезней факультета фундаментальной медицины МГУ им. М.В. Ломоносова, Москва

Кафедра внутренних болезней факультета фундаментальной медицины МГУ им. М.В. Ломоносова, Москва

E A Saginova

M G Gallyamov

M M Severova

Список литературы

  1. Hoefle G., Saely C.H., Aczel S. et al. Impact of central and total obesity on vascular mortality in patients undergoing coronary angiography. Int. J. Obes. 2005; 29: 785 - 791
  2. Rea D.J., Heimbach J.K., Grande J.P. et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int. 2006; 70(9): 1636 - 1641
  3. Despres J.-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur. Heart J. 2006; 8 (Suppl. B): B4 - B12
  4. Iseki K., Ikemiya Y., Kinjo K. et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004; 65 (5): 1870 - 1876
  5. Gelber R.P., Kurth T., Kausz A.T. et al. Association between body mass index and CKD in apparently healthy men. Am. J. Kidney Dis. 2005; 46: 871 - 880
  6. Kougias P., Chai H., Lin P.H. et al. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J. Vasc. Surg. 2005; 41: 691 - 698
  7. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J.A.M.A. 2002; 287 (3): 356 - 359
  8. Сhen J., Muntner P., Hamm L. et al. The metabolic syndrome and chronic kidney disease in U.S. Adults. Ann. Intern. Med. 2004; 140: 167 - 174.
  9. Wang Y., Cheng Х. et al. Aassociation between obesity and kidney diseases: A systematic review and meta-analysis. Kidney Int., 2008; 73: 18 - 23
  10. Wolf G. Obesity and renal hemodynamics. Contrib Nephrol. 2006; 151: 184-202
  11. Сагинова Е.А., Федорова Е.Ю., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер. архив 2006; 36-41
  12. Kasiske B.L., Crosson J.T. Renal disease in patients with massive obesity. Arch. Intern. Med. 1986; 146 (6): 1105 - 1109
  13. Praga M., Hernandez E., Morales E. Clinical features and long-term outcome of obesity- associated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant 2001; 15: 1790 - 1798
  14. Kasiske B.L., Napier J. Glomerular sclerosis in patients with massive obesity. Am. J. Nephrol. 1985; 5 (1): 45 - 50
  15. Sasatomi Y., Tada M., Uesugi N. et al. Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology. 2001; 69 (2): 113 - 118
  16. Rea D.J., Heimbach J.K., Grande J.P. et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int. 2006; 70(9): 1636 - 1641
  17. Orfila C., Lepert J.C., Modesto A. et al. IgA nephropathy complicating diabetic glomerulosclerosis. Nephron. 1998; 79(3):279-287
  18. Amore A., Roccatello D., Picciotto G., Emancipator S.N. Processing of IgA aggregates in a rat model of chronic liver disease. Clin Immunol Immunopathol. 1997; 84(2):107-114.
  19. Despres J.-P., Lemieux I., Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. B.M.J. 2001; 322: 716 - 720
  20. Hall J.E., Brands M.W., Henegar J.R. Mechanisms of hypertension and kidney disease in obesity. Ann. N. Y. Acad. Sci. 1999; 892: 91 - 107
  21. Wicek A., Kokot F., Chudek J., Adamczak M. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol. Dial. Transplant. 2002; 17:191 - 195
  22. Gunter W., Sheldon C., Han D.C. et al. Leptin and renal disease. Am. J. Kidney Dis. 2002; 39: 1 - 11
  23. Wolf G., Ziyadeh F.N. Leptin and renal fibrosis. Contrib. Nephrol. 2006; 151: 175 - 183
  24. Han D.C., Isono M., Chen S. et al. Leptin stimulates type I collagen production in db/db mesangial cells, glucose uptake and TGF-b type II receptor expression. Kidney Int. 2001; 59: 1315-1323
  25. Wolf G., Hamann A., Han D.C. et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999; 6(3): 860-872
  26. Stam F, van Guldener C, Becker A. et al. Endothelial dysfunction contributes to renal functionassociated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J. Am. Soc. Nephrol. 2006; 17: 537-545
  27. Quehenberger P., Exner M., Sunder-Plassmann R. et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ. Res. 2002; 90: 711 - 718
  28. Turner N.C., Morgan P.J., Haynes A.C. et al. Elevated renal endothelin-I clearance and mRNA levels associated with albuminuria and nephropathy in non-insulin-dependent diabetes mellitus: studies in obese fa/fa Zucker rats. Clin. Sci. (Lond). 1997; 93: 565 - 571
  29. Barton M., Carmona R., Morawietz H. et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension. 2000; 35 (1 Pt. 2): 329 - 336
  30. Mather K.J., Lteif A., Steinberg H.O., Baron A.D. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004; 53: 2060 - 2066
  31. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens. 2006; 24(4): 611-619
  32. Palm F., Onozato M.L., Luo Z., Wilcox C.S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007; 293(6): H3227-H3245
  33. Masuda H., Goto M., Tamaoki S., Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol. 1999; 126(1): 211-218
  34. Valkonen V.P., Tuomainen T.P., Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med. 2005; 10 (Suppl 1):S45-S48
  35. Krzyzanowska K, Mittermayer F, Kopp HP et al. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab. 2004; 89(12): 6277-6281
  36. Ito A., Tsao P.S., Adimoolam S. et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999; 99(24): 3092-3095
  37. Caglar K., Yilmaz M.I., Sonmez A. et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006; 70(4): 781-787
  38. Fliser D., Kronenberg F., Kielstein J.T. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005; 16(8): 2456-2461
  39. Nieuwdorp M., Meuwese M.C., Vink H. et al. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol. 2005; 16(5): 507-511
  40. Rana J.S., Nieuwdorp M., Jukema J.W., Kastelein J.J. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes. Metab. 2007; 9(3):218-232
  41. Wang W. Change in properties of the glycocalyx affects the shear rate and stress distribution on endothelial cells. J Biomech. Eng. 2007; 129(3):324-329
  42. Goligorsky M.S. Clinical assessment of endothelial dysfunction: combine and rule. Curr Opin Nephrol Hypertens. 2006; 15(6):617-624
  43. Rubio-Gayosso I., Platts S.H., Duling B.R. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2006; 290(6): H2247-H2256
  44. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50 - 55
  45. Yuyun M., Alder A.I., Wareham N.J. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events. Curr. Opin. Nephrol. Hypertens. 2005; 14: 271 - 276
  46. Schiffrin E.L., Touyz R.M. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am. J. Physiol Heart Circ. Physiol. 2004;287: H435-H446
  47. Touyz R.M., Schiffrin E.L. Reactive oxygen species in vascular biology: implications in hypertension. Histochem. Cell Biol. 2004;122:339 -352.
  48. Vendrell J., Broch M., Vilarrasa N. et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes. Res. 2004; 12(6): 962 - 971
  49. Wu Y., Liu Z., Xiang Z. et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006; 147(1): 44 - 50
  50. Heimbach J.K., Taler S.J., Prieto M. et al. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am. J. Transplant. 2005; 5(5): 1057-1064
  51. Pesavento T.E., Henry M.L., Falkenhain M.E. et al. Obese living kidney donors: short-term results and possible implications. Transplantation. 1999; 68(10): 1491 - 1496.
  52. Espinoza R., Gracida C., Cancino J., Ibarra A. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant. Proc. 2006; 38(3): 888-889
  53. Stevenson F.T., Wheeldon C.M., Gades M.D. et al. Hyperphagia as a mediator of renal disease initiation in obese Zucker rats. Obes. Res. 2001; 9(8): 492 - 499
  54. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005; 365: 1415 - 1428
  55. Uribarri J., Katherine R. Tuttle Advanced Glycation End Products and Nephrotoxicity of High-Protein Diets, Clin. J. Am. Soc. Nephrol. 2006; 1: 1293-1299
  56. Wadden T.A., Berkowitz R.I., Womble L.G. et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 2005; 353: 2111 - 2120
  57. Barbaro D., Orsini P., Pallini S. et al. Obesity in transplant patients: case report showing interference of orlistat with absorbtion of cyclosporine and review of literature. Endocr. Pract. 2002; 8(2): 124 - 126
  58. Errasti P., Garcia I., Lavilla J. et al. Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. Transplant Proc. 2002; 34(1): 137 - 139
  59. Evans S., Michael R., Wells. H. et al. Drug interaction in a renal transplant patient: cyclosporine-Neoral and orlistat. Am. J. Kidney Dis. 2003; 41(2): 493 - 496
  60. Chagnac A., Weinstein T., Herman M. et al. The effects of weight loss on renal function in patients with severe obesity. J. Am. Soc. Nephrol. 2003; 14: 1480 - 1486.
  61. Sharma S.K., McCauley J., Cottam D. et al. Acute changes in renal function after laparoscopic gastric surgery for morbid obesity. Surg. Obes. Relat. Dis. 2006; 2(3): 389-392
  62. Parving H.H., Lenhert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870 - 878
  63. Praga M., Hernandez E., Morales E. et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 2001; 16(9): 1790 - 1798
  64. Blanco S., Vaquero M., Gomez-Guerrero C. et al. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am. J. Hypertens. 2005; 18 (4 Pt. 1): 557-565
  65. Adelman R.D., Restaino I.G., Alon U.S., Blowey D.L. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J. Pediatr. 2001; 138 (4): 481 - 485
  66. Kurata A., Nishizawa H., Kihara S. et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006; 70(10): 1717-1724
  67. Parving H, Persson F., Lewis J. at al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N.Engl.J.Med. 2008; 358(23):2433-2446
  68. Kielstein J.T., Fliser D. Lowering asymmetric dimethylarginine-a new mechanism mediating the renoprotective effects of renin-angiotensin system inhibitors in proteinuric patients? Blood Purif. 2007;25(4):324-6.
  69. Teplan V., Schück O., Racek J. et al. Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial. Wien Klin. Wochenschr. 2008; 120(15-16):478-485
  70. Nathan D.M. Thiazolidinediones for initial treatment of type 2 diabetes? N. Engl. J. Med. 2006; 355(23): 2477 - 2480

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах